Protein/Protein Interactions in the Mammalian Heme Degradation Pathway

Background: Heme oxygenase, cytochrome P450 reductase, and biliverdin reductase are the key enzymes in heme degradation. Results: Specific electrostatic and hydrophobic interactions form the binding interface between heme oxygenase and cytochrome P450 reductase. Conclusion: Heme oxygenase binds cytochrome P450 reductase dynamically and biliverdin reductase very weakly. Significance: Characterizing interactions among proteins involved in heme degradation are crucial to understanding heme homeostasis. Heme oxygenase (HO) catalyzes the rate-limiting step in the O2-dependent degradation of heme to biliverdin, CO, and iron with electrons delivered from NADPH via cytochrome P450 reductase (CPR). Biliverdin reductase (BVR) then catalyzes conversion of biliverdin to bilirubin. We describe mutagenesis combined with kinetic, spectroscopic (fluorescence and NMR), surface plasmon resonance, cross-linking, gel filtration, and analytical ultracentrifugation studies aimed at evaluating interactions of HO-2 with CPR and BVR. Based on these results, we propose a model in which HO-2 and CPR form a dynamic ensemble of complex(es) that precede formation of the productive electron transfer complex. The 1H-15N TROSY NMR spectrum of HO-2 reveals specific residues, including Leu-201, near the heme face of HO-2 that are affected by the addition of CPR, implicating these residues at the HO/CPR interface. Alanine substitutions at HO-2 residues Leu-201 and Lys-169 cause a respective 3- and 22-fold increase in Km values for CPR, consistent with a role for these residues in CPR binding. Sedimentation velocity experiments confirm the transient nature of the HO-2·CPR complex (Kd = 15.1 μm). Our results also indicate that HO-2 and BVR form a very weak complex that is only captured by cross-linking. For example, under conditions where CPR affects the 1H-15N TROSY NMR spectrum of HO-2, BVR has no effect. Fluorescence quenching experiments also suggest that BVR binds HO-2 weakly, if at all, and that the previously reported high affinity of BVR for HO is artifactual, resulting from the effects of free heme (dissociated from HO) on BVR fluorescence.

[1]  M. Maines,et al.  Nuclear localization of biliverdin reductase in the rat kidney: response to nephrotoxins that induce heme oxygenase-1. , 2001, The Journal of pharmacology and experimental therapeutics.

[2]  P. Ortiz de Montellano,et al.  Role of Cysteine Residues in Heme Binding to Human Heme Oxygenase-2 Elucidated by Two-dimensional NMR Spectroscopy* , 2012, The Journal of Biological Chemistry.

[3]  M. Maines,et al.  Site-directed mutagenesis of cysteine residues in biliverdin reductase. Roles in substrate and cofactor binding. , 1994, European journal of biochemistry.

[4]  Solomon H. Snyder,et al.  Biliverdin reductase: A major physiologic cytoprotectant , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Hideaki Sato,et al.  Structural basis for the electron transfer from an open form of NADPH-cytochrome P450 oxidoreductase to heme oxygenase , 2014, Proceedings of the National Academy of Sciences.

[6]  H. Kamin,et al.  Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. , 1962, The Journal of biological chemistry.

[7]  P. Ortiz de Montellano,et al.  Reaction Intermediates and Single Turnover Rate Constants for the Oxidation of Heme by Human Heme Oxygenase-1* , 2000, The Journal of Biological Chemistry.

[8]  Danielson Pb,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002 .

[9]  M. Maines,et al.  The heme oxygenase system: a regulator of second messenger gases. , 1997, Annual review of pharmacology and toxicology.

[10]  B. Masters,et al.  Diminished FAD Binding in the Y459H and V492E Antley-Bixler Syndrome Mutants of Human Cytochrome P450 Reductase* , 2006, Journal of Biological Chemistry.

[11]  P. B. Crowley,et al.  Close encounters of the transient kind: protein interactions in the photosynthetic redox chain investigated by NMR spectroscopy. , 2003, Accounts of chemical research.

[12]  Gary Patterson,et al.  Physical Chemistry of Macromolecules , 2007 .

[13]  J. Roder,et al.  Heme oxygenase 2 , 1998 .

[14]  S. Ragsdale,et al.  Evidence That the Heme Regulatory Motifs in Heme Oxygenase-2 Serve as a Thiol/Disulfide Redox Switch Regulating Heme Binding* , 2007, Journal of Biological Chemistry.

[15]  H. Marver,et al.  Microsomal heme oxygenase. Characterization of the enzyme. , 1969, The Journal of biological chemistry.

[16]  M. Maines,et al.  Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. , 1997, European journal of biochemistry.

[17]  M. Moore Characterization of the enzyme , 1994 .

[18]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[19]  G. Kikuchi,et al.  Inability of the NADH‐cytochrome b 5 reductase system to initiate heme degradation yielding biliverdin IXα from the oxygenated form of heme · heme oxygenase complex , 1980, FEBS letters.

[20]  M. Maines The heme oxygenase system: update 2005. , 2005, Antioxidants & redox signaling.

[21]  H. Sakamoto,et al.  Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. , 2004, Gene.

[22]  M. Maines,et al.  Human Biliverdin Reductase Is a Leucine Zipper-like DNA-binding Protein and Functions in Transcriptional Activation of Heme Oxygenase-1 by Oxidative Stress* , 2002, The Journal of Biological Chemistry.

[23]  M. Busker,et al.  Heme Oxygenase Isoforms Differ in Their Subcellular Trafficking during Hypoxia and Are Differentially Modulated by Cytochrome P450 Reductase , 2012, PloS one.

[24]  H. Enoch,et al.  Cytochrome b5 reduction by NADPH-cytochrome P-450 reductase. , 1979, The Journal of biological chemistry.

[25]  L. Otterbein,et al.  Carbon Monoxide and the brain: time to rethink the dogma. , 2013, Current pharmaceutical design.

[26]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[27]  H. Kalbitzer,et al.  Protein NMR Spectroscopy. Principles and Practice , 1997 .

[28]  M. Maines,et al.  Heme oxygenase-2 interaction with metalloporphyrins: function of heme regulatory motifs. , 2001, Antioxidants & redox signaling.

[29]  S. Sassa Why Heme Needs to Be Degraded to Iron, Biliverdin IXα, and Carbon Monoxide? , 2004 .

[30]  J. Potts,et al.  Recent Developments in Biomolecular NMR , 2012 .

[31]  H. Sakamoto,et al.  Involvement of NADP(H) in the Interaction between Heme Oxygenase-1 and Cytochrome P450 Reductase* , 2005, Journal of Biological Chemistry.

[32]  P. Schuck,et al.  Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. , 2000, Biophysical journal.

[33]  M. Maines,et al.  Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling , 2008, Proceedings of the National Academy of Sciences.

[34]  R. Riek,et al.  Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Münzel,et al.  Conversion of biliverdin to bilirubin by biliverdin reductase contributes to endothelial cell protection by heme oxygenase-1-evidence for direct and indirect antioxidant actions of bilirubin. , 2010, Journal of molecular and cellular cardiology.

[36]  D. Gemsa MICROSOMAL HEME OXYGENASE , 1981 .

[37]  P. Danielson,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002, Current drug metabolism.

[38]  A. Palmer,et al.  Protein NMR Spectroscopy: principles and practice, 2nd ed. , 2006 .

[39]  K. Bloch,et al.  Solubilization and partial characterization of rat liver squalene epoxidase. , 1975, The Journal of biological chemistry.

[40]  N. Andrews,et al.  Iron homeostasis. , 2007, Annual review of physiology.

[41]  S. Ryter,et al.  CO as a cellular signaling molecule. , 2006, Annual review of pharmacology and toxicology.

[42]  Paul M. Jenkins,et al.  Heme Regulatory Motifs in Heme Oxygenase-2 Form a Thiol/Disulfide Redox Switch That Responds to the Cellular Redox State* , 2009, The Journal of Biological Chemistry.

[43]  M. Maines,et al.  Small Interference RNA-mediated Gene Silencing of Human Biliverdin Reductase, but Not That of Heme Oxygenase-1, Attenuates Arsenite-mediated Induction of the Oxygenase and Increases Apoptosis in 293A Kidney Cells* , 2005, Journal of Biological Chemistry.

[44]  M. Maines Carbon Monoxide: An Emerging Regulator of cGMP in the Brain , 1993, Molecular and Cellular Neuroscience.

[45]  A. D. McLachlan,et al.  Introduction to magnetic resonance : with applications to chemistry and chemical physics , 1967 .

[46]  Benveniste,et al.  Cytochrome P450 , 1993, Handbook of Experimental Pharmacology.

[47]  M. Maines,et al.  Purification and characterization of biliverdin reductase from rat liver. , 1981, The Journal of biological chemistry.

[48]  S. Snyder,et al.  Bilirubin and glutathione have complementary antioxidant and cytoprotective roles , 2009, Proceedings of the National Academy of Sciences.

[49]  M. H. Quenouille NOTES ON BIAS IN ESTIMATION , 1956 .

[50]  M. Ikeda-Saito,et al.  Heme oxygenase reveals its strategy for catalyzing three successive oxygenation reactions. , 2010, Accounts of chemical research.

[51]  P. Hollenberg,et al.  Uncovering the role of hydrophobic residues in cytochrome P450-cytochrome P450 reductase interactions. , 2011, Biochemistry.

[52]  E. Wood,et al.  Data for Biochemical Research, 3rd Edn , 1987 .

[53]  A. Hodgson,et al.  NADPH Cytochrome P450 Reductase and Its Structural and Functional Domains , 1995 .

[54]  M. Maines,et al.  Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  D. Nelson,et al.  Cytochrome P-450: cytochrome P-450 reductase interactions. , 1989, Drug metabolism reviews.

[56]  W. H. Elliott,et al.  Data for Biochemical Research , 1986 .

[57]  J. Forman-Kay,et al.  CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices , 2007, Nature Structural &Molecular Biology.

[58]  Julie D. Forman-Kay,et al.  Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding , 2012, Nucleic acids research.

[59]  Cicerone Tudor,et al.  Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin. , 2008, The Biochemical journal.

[60]  M. Ubbink The courtship of proteins: Understanding the encounter complex , 2009, FEBS letters.

[61]  M. Maines New insights into biliverdin reductase functions: linking heme metabolism to cell signaling. , 2005, Physiology.

[62]  J. Cavanagh Protein NMR Spectroscopy: Principles and Practice , 1995 .

[63]  B. Masters,et al.  Measurement of Membrane-Bound Human Heme Oxygenase-1 Activity Using a Chemically Defined Assay System , 2009, Drug Metabolism and Disposition.

[64]  G. Phillips,et al.  Comparison of Apo- and Heme-bound Crystal Structures of a Truncated Human Heme Oxygenase-2* , 2007, Journal of Biological Chemistry.

[65]  H. Zhou,et al.  Identification of Histidine 45 as the Axial Heme Iron Ligand of Heme Oxygenase-2* , 1998, The Journal of Biological Chemistry.

[66]  H. Sakamoto,et al.  Mass spectrometric identification of lysine residues of heme oxygenase-1 that are involved in its interaction with NADPH-cytochrome P450 reductase. , 2008, Biochemical and biophysical research communications.

[67]  31P NMR study of the kinetics of binding of myo-inositol hexakisphosphate to human hemoglobin. Observation of fast-exchange kinetics in high-affinity systems. , 1981, European journal of biochemistry.

[68]  M. Maines The heme oxygenase system: past, present, and future. , 2004, Antioxidants & redox signaling.

[69]  P. D. de Montellano,et al.  The Binding Sites on Human Heme Oxygenase-1 for Cytochrome P450 Reductase and Biliverdin Reductase* , 2003, Journal of Biological Chemistry.

[70]  S. Sassa Why heme needs to be degraded to iron, biliverdin IXalpha, and carbon monoxide? , 2004, Antioxidants & redox signaling.

[71]  R. Mariuzza,et al.  Sedimentation velocity analysis of heterogeneous protein-protein interactions: Lamm equation modeling and sedimentation coefficient distributions c(s). , 2005, Biophysical journal.

[72]  Kiriko Kaneko,et al.  Heme as a magnificent molecule with multiple missions: heme determines its own fate and governs cellular homeostasis. , 2007, The Tohoku journal of experimental medicine.

[73]  P. D. de Jong,et al.  Ligation-independent cloning of PCR products (LIC-PCR). , 1990, Nucleic acids research.